MX2022006783A - Nuevos derivados de metilquinazolinona. - Google Patents
Nuevos derivados de metilquinazolinona.Info
- Publication number
- MX2022006783A MX2022006783A MX2022006783A MX2022006783A MX2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A
- Authority
- MX
- Mexico
- Prior art keywords
- methylquinazolinone
- derivatives
- new
- compound
- formula
- Prior art date
Links
- RLLNOZZVLWEBBI-UHFFFAOYSA-N 4-methyl-3h-quinazolin-2-one Chemical class C1=CC=CC2=C(C)NC(=O)N=C21 RLLNOZZVLWEBBI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Combines (AREA)
- Harvester Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006783A true MX2022006783A (es) | 2022-07-11 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006783A MX2022006783A (es) | 2019-12-10 | 2020-12-08 | Nuevos derivados de metilquinazolinona. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (https=) |
| EP (2) | EP4483882A3 (https=) |
| JP (2) | JP7108146B2 (https=) |
| KR (1) | KR102836833B1 (https=) |
| CN (2) | CN114787156B (https=) |
| AR (1) | AR122351A1 (https=) |
| AU (1) | AU2020403443B2 (https=) |
| CL (1) | CL2022001529A1 (https=) |
| CO (1) | CO2022008968A2 (https=) |
| CR (1) | CR20220251A (https=) |
| DK (1) | DK4073065T3 (https=) |
| ES (1) | ES3023264T3 (https=) |
| FI (1) | FI4073065T3 (https=) |
| HR (1) | HRP20250418T1 (https=) |
| HU (1) | HUE071148T2 (https=) |
| IL (2) | IL316473A (https=) |
| LT (1) | LT4073065T (https=) |
| MA (1) | MA58087B1 (https=) |
| MX (1) | MX2022006783A (https=) |
| PE (1) | PE20221778A1 (https=) |
| PH (1) | PH12022551119A1 (https=) |
| PL (1) | PL4073065T3 (https=) |
| PT (1) | PT4073065T (https=) |
| RS (1) | RS66721B1 (https=) |
| SI (1) | SI4073065T1 (https=) |
| TW (2) | TWI877268B (https=) |
| UA (1) | UA128299C2 (https=) |
| WO (1) | WO2021116055A1 (https=) |
| ZA (2) | ZA202204675B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| IL307964A (en) * | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
| CA3216220A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| MX2023014629A (es) * | 2021-06-09 | 2024-01-30 | Hoffmann La Roche | Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida. |
| KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4426305A1 (en) | 2021-11-04 | 2024-09-11 | F. Hoffmann-La Roche AG | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| EP4618994A1 (en) | 2022-11-18 | 2025-09-24 | F. Hoffmann-La Roche AG | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| TW202438072A (zh) * | 2022-12-15 | 2024-10-01 | 瑞士商赫孚孟拉羅股份公司 | 製備喹唑啉酮衍生物之方法 |
| KR20260032991A (ko) | 2023-07-04 | 2026-03-10 | 에프. 호프만-라 로슈 아게 | (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| TW202545530A (zh) * | 2024-01-17 | 2025-12-01 | 大陸商海思科醫藥集團股份有限公司 | 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用 |
| WO2026037755A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | New methylquinazolinone derivatives |
| WO2026046946A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3147281A1 (en) | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| AU2013318283A1 (en) | 2012-09-19 | 2015-03-05 | Novartis Ag | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
| CN105228983A (zh) | 2013-05-30 | 2016-01-06 | 普莱希科公司 | 用于激酶调节的化合物及其适应症 |
| US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| JP2023554062A (ja) | 2020-12-18 | 2023-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規アリール－ピリド－ピリミジン－オン誘導体 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| US20250011304A1 (en) | 2021-12-08 | 2025-01-09 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
-
2020
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 TW TW113139852A patent/TWI908405B/zh active
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
-
2021
- 2021-12-14 JP JP2021202780A patent/JP7802514B2/ja active Active
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| PH12020500673A1 (en) | Compounds | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201990952A1 (ru) | ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MX2016014939A (es) | Derivados de carboxamida. | |
| BR112018074985A2 (pt) | composições antibacterianas | |
| MX383577B (es) | Derivados sustituidos de guanidina. | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX379576B (es) | Derivados de azetidina | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| EA202190458A1 (ru) | Составы, содержащие дендример | |
| MY208423A (en) | Composition of aminopyran derivative |